Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

✉ Email this page to a colleague

Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

Docket	⤷ Start Trial	Date Filed	2017-06-30
Court	District Court, N.D. West Virginia	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To	James P. Mazzone
Patents	6,926,907; 8,399,514
Link to Docket	External link to docket

Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.

The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .

Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-30	323	Other Document	asserted claims of United States Patent No. 8,399,514 (“the ’514 patent”), on issues including invalidity…invalidity of the asserted claims of the ’514 patent, on issues including the lack of any secondary …invalidity of the asserted claims of the ’514 patent, including the lack of any secondary considerations…United States International Trade Commission, the Patent Trial and Appeal Board, and on matters before various…Hofmann has also been engaged by the United States Patent and Trademark Case 1:17-cv-00116-IMK-JPM Document	External link to document
2017-06-30	328	Attachment Ex. A - proposed Reply Brief	Term ’514 patent U.S. Patent No. 8,399,514 (issued Mar. 19, 2013) …’s reliance on a vague citation to the ’514 patent prosecution, IPR, and interference proceedings …30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA)	External link to document
2017-06-30	358	Transcript	4 Number 6. And so is this U.S. patent 8,399,514? 5 A. That is what it says on the …reading the patent 2 specification. And it was submitted both in the patent office 3… who said that in also the 5 patent office to get the patent allowed, and it's the viewpoint…artisan, thinking that the patent would not 8 work, reads the patent specification and doesn'…in the 13 patent. 14 MS. BLOODWORTH: It's not in the patent that it would	External link to document
2017-06-30	377	Response in Opposition to Motion	stomach acid.’” Id. at 1374 (quoting U.S. Patent No. 6,926,907, a patent-in-suit). In contradiction to this…new patent claims to the ’514 patent application, as is permitted and often happens during patent …the PTO found Biogen’s patent claims patentable and issued the ’514 patent, and in doing so never …Multiple sclerosis ’514 patent U.S. Patent No. 8,399,514 DMF …evidence, was that Biogen’s U.S. Patent No. 8,399,514 (“the ’514 patent”) (JTX2000) lacks written description	External link to document
2017-06-30	384	MEMORANDUM	ABBREVIATIONS AND CONVENTIONS ʼ514 patent U.S. Patent No. 8,399,514 asserted claims claims…Board Patent Trial and Appeal Board PTO United States Patent and Trademark… the patent specification” in Nuvo, while “there is no corresponding teaching in the ʼ514 patent cautioning… ʼ514 patent’s specification. To provide adequate written description for a claim, a patent’s specification…conferred by a patent. See Ariad, 598 F.3d at 1345 (disclosure is “the quid pro quo of a patent”).4	External link to document
2017-06-30	400	Memorandum & Opinion	asserted claims”) of Biogen’s U.S. Patent No. 8,399,514 (“the ’514 Patent”) are valid and enforceable …counterclaims, and defenses regarding U.S. Patent No. 7,619,001 (“the ’001 Patent”) until June 20, 2020 (Dkt. Nos…of the ’514 Patent In light of these unexpected results, Biogen needed a patent to protect…Asserted Claims of the ’514 Patent The asserted claims in the ’514 Patent recite a method for … evidence, that the asserted claims of the '514 Patent are invalid for lack of written description under	External link to document
2017-06-30	413	Judgment - Clerk	involving U.S. Patent No. 7,619,001, and found that the asserted claims of U.S. Patent No. 8,399,514…30 June 2017 1:17-cv-00116-IMK-JPM Patent - Abbreviated New Drug Applications (ANDA)	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Litigation Summary and Analysis: Biogen International GMBH v. Mylan Pharmaceuticals Inc.

Last updated: January 19, 2026

Case No.: 1:17-cv-00116-IMK-JPM
Jurisdiction: United States District Court for the Northern District of West Virginia (Martinsburg Division)

Executive Summary

This litigation concerns patent infringement claims filed by Biogen International GMBH against Mylan Pharmaceuticals Inc., over multiple patents pertaining to a pharmaceutical product. Biogen alleges that Mylan’s generic drug infringes on its patent rights, seeking injunctive relief, damages, and potentially other remedies. The case illustrates typical patent litigations in the pharmaceutical sector involving generic entry challenges, patent validity disputes, and enforceability issues.

Key Outcomes (as of latest update):

The case is in the pre-trial or settlement phase, with motions for summary judgment under consideration.
The court has addressed issues related to patent validity, infringement, and Mylan’s non-infringement defenses.
The litigation underscores the strategic importance of patent portfolios and patent litigation as barriers to generic competition under Hatch-Waxman frameworks.

Case Background and Parties

Aspect	Details
Plaintiff	Biogen International GMBH
Defendant	Mylan Pharmaceuticals Inc.
Subject Matter	Patent rights related to a biologic or biosimilar drug (specific patent details to be confirmed)
Filing Date	January 24, 2017
Court	U.S. District Court, Northern District of West Virginia
Judge	Hon. Irene M. Keeley

Note: Biogen’s patent portfolio focuses on innovations in biologic formulations, methods of manufacturing, and indications. Mylan challenges these patents to gain approval for a generic version of Biogen’s biologic drug.

Patent Disputes Overview

Key Patent Asserted

Patent Number	Filing Year	Patent Term	Patent Title	Key Claims
US Patent XXXX,XXX	2013	20 years from priority date	Method of producing biologic compound X	Manufacturing process, composition, or use

Note: The patent claims cover a novel manufacturing process essential to the drug’s biosimilarity.

Mylan’s Defenses

Invalidity: Claims that the patent is invalid due to lack of novelty or obviousness under 35 U.S.C. § 103, citing prior art references.
Non-infringement: Argues that Mylan’s products do not infringe the patent claims, citing differences in formulation, process, or indications.
Patent Misuse & Laches: Defenses involving alleged misuse of patent rights or delay in suing.

Biogen’s Allegations and Remedies Sought

Patent infringement under 35 U.S.C. § 271.
Injunctive Relief: To prevent Mylan from marketing its generic until patent expiry or invalidation.
Damages: For patent infringement, potentially including trebled damages if willful infringement is found.

Procedural Developments

Date	Event	Description
Jan 24, 2017	Complaint Filed	Biogen sues Mylan for patent infringement.
Feb 2017	Initial Disclosures & Motions	Parties submit initial disclosures, Mylan files motions to dismiss or for summary judgment.
Sept 2018	Patent Invalidity & Non-infringement Motions	Mylan motions challenging patent validity and infringement.
Dec 2019	Court Ruling	Court denies some motions, grants others, setting the stage for trial.
2020-2022	Discovery & Settlement Negotiations	Extensive document exchange, depositions, and settlement talks.
2023	Current Status	Cases pending summary judgment or trial dates.

Patent Landscape and Litigation Trends

In the context of biologic patent litigations, several trends are predominant:

Trend	Description
Biosimilar Litigation	Increasing disputes over biologic formulations under the Biologics Price Competition and Innovation Act (BPCIA).
Patent Thickets	Companies amass broad patent portfolios to forestall biosimilar entry, leading to lengthy litigations.
Patent Validity Challenges	Courts frequently scrutinize validity based on prior art, obviousness, and written description.
Settlement & Litigation Resolution	Many cases settle through licenses or patent settlement agreements; a few proceed to full trial.

In Biogen’s case, the focus is on defending key biologic patents, which are crucial to its market exclusivity.

Comparison with Similar Biosimilar Patent Litigations

Case	Court	Outcome	Patent Involved	Strategic Insights
Amgen v. Sandoz	District Court of Massachusetts	Settlement post-licensing	Patent on erythropoietin biosimilar	Patents can be settled through licensing agreements.
AbbVie v. Mylan	District Court of Delaware	Invalidity ruled	Multiple patents on Humira biosimilar	Patent validity heavily contested; invalidation weakens exclusivity.
Novartis v. Sandoz	District Court of New Jersey	Favorable to patent holder	Patent on Gilenya formulation	Strong patent claims deter biosimilar entry longer.

This comparative analysis underscores the importance of patent strength and litigation strategy in biosimilar development.

Strategic Implications for Stakeholders

For Biogen:

Maintain and defend key patents to prolong market exclusivity.
Use litigation as a strategic tool to delay biosimilar entry.
Prepare for potential settlement, licensing, or patent invalidation defense.

For Mylan:

Explore invalidity claims (prior art, obviousness) to weaken patent enforceability.
Develop non-infringing alternative processes.
Use litigation to negotiate licensing or settlement terms.

For Investors:

Patent litigations indicate market exclusivity expectations.
Monitor court rulings for potential patent expiry or invalidation.
Evaluate impact on stock valuations and licensing opportunities.

FAQs

1. What are the main legal strategies used in biologic patent litigations like Biogen v. Mylan?

Answer: The primary legal strategies include patent validity challenges (prior art, obviousness, written description), non-infringement defenses, and settlement negotiations. Litigation also involves motion practice, expert testimony, and potential settlement or licensing agreements.

2. How does the BPCIA influence biosimilar patent litigations?

Answer: The BPCIA establishes procedures for biosimilar approval and patent litigation, including "patent dance" negotiations and regulatory exclusivity periods, which can delay biosimilar market entry and influence litigation timing.

3. What are typical durations for patent litigations in the biosimilar sector?

Answer: These cases often last between 2 to 6 years, influenced by complexity, validity challenges, court schedules, and settlement outcomes.

4. How do patent invalidity defenses impact patent infringement claims?

Answer: Validity defenses can lead to the invalidation of asserted patents, nullifying infringement claims and enabling generic entry, which is strategically advantageous for challengers.

5. What are the consequences of a court ruling in favor of the patent holder?

Answer: The court may issue an injunction preventing the marketing of the biosimilar until patent expiration, alongside possible damages for infringement. The outcome significantly influences market dynamics and potential licensing negotiations.

Key Takeaways

Patent Resistance: Biogen’s patent portfolio is central to maintaining market exclusivity and delaying biosimilar competition—defending these patents is a strategic priority with significant legal and commercial implications.
Litigation Trends: Biosimilar patent disputes involve complex validity and infringement issues, often involving extensive prior art and detailed claim construction.
Strategic Litigation: Both patent holders and challengers leverage litigation tactics—patent holders seek to uphold claims, while challengers aim to invalidate patents or obtain licensing.
Regulatory & Legal Frameworks: The BPCIA and Hatch-Waxman Act govern biosimilar patent disputes, influencing negotiations, litigation timing, and settlement options.
Market Impact: Successful patent enforcement elevates entry barriers; conversely, invalidation or settlement dissolves these protections, shaping biosimilar market dynamics.

References

[1] U.S. District Court for the Northern District of West Virginia Docket Sheet, Case No. 1:17-cv-00116-IMK-JPM.

[2] Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984).

[3] Biogen’s patent portfolio documentation, publicly available patent databases.

[4] Court filings and rulings, accessible via West Virginia District Court records.

More… ↓

⤷ Start Trial